Cancer research: Latest News, Top Stories & Analysis

Idera Pharmaceuticals Announces Preliminary Data From and Planned Continuation of the ILLUMINATE-206 Trial

June 3, 2020June 3, 2020 - by MyChesCo

EXTON, PA — Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) announced preliminary data from the first 10 patients in the safety cohort of ILLUMINATE-206, a Phase 2, open-label, multi-center study to evaluate …

Cancer / Products and Services / Research

Idera Pharmaceuticals Announces Final Clinical Safety and Efficacy Data from ILLUMINATE-204 Trial in Advanced Melanoma

April 22, 2020April 22, 2020 - by MyChesCo

EXTON, PA — Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) announced final topline data from the ILLUMINATE-204 trial investigating intratumoral tilsotolimod, Idera’s investigational Toll-like receptor 9 (TLR9) agonist.